52
|
Wang Y, Yan L, Liu J, Chen S, Liu G, Nie Y, Wang P, Yang W, Chen L, Zhong X, Han S, Zhang L. The HNF1 α-Regulated LncRNA HNF1 α-AS1 Is Involved in the Regulation of Cytochrome P450 Expression in Human Liver Tissues and Huh7 Cells. J Pharmacol Exp Ther 2019; 368:353-362. [PMID: 30602592 DOI: 10.1124/jpet.118.252940] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2018] [Accepted: 12/04/2018] [Indexed: 12/20/2022] Open
Abstract
Expression of cytochrome P450s (P450s) is regulated by epigenetic factors, such as DNA methylation, histone modifications, and noncoding RNAs through different mechanisms. Among these factors, long noncoding RNAs (lncRNAs) have been shown to play important roles in the regulation of gene expression; however, little is known about the effects of lncRNAs on the regulation of P450 expression. The aim of this study was to explore the role of lncRNAs in the regulation of P450 expression by using human liver tissues and hepatoma Huh7 cells. Through lncRNA microarray analysis and quantitative polymerase chain reaction in human liver tissues, we found that the lncRNA hepatocyte nuclear factor 1 alpha antisense 1 (HNF1α-AS1), an antisense RNA of HNF1α, is positively correlated with the mRNA expression of CYP2C8, 2C9, 2C19, 2D6, 2E1, and 3A4 as well as pregnane X receptor (PXR) and constitutive androstane receptor (CAR). Gain- and loss-of-function studies in Huh7 cells transfected with small interfering RNAs or overexpression plasmids showed that HNF1α not only regulated the expression of HNF1α-AS1 and P450s, but also regulated the expression of CAR, PXR, and aryl hydrocarbon receptor (AhR). In turn, HNF1α-AS1 regulated the expression of PXR and most P450s without affecting the expression of HNF1α, AhR, and CAR. Moreover, the rifampicin-induced expression of P450s was also affected by HNF1α and HNF1α-AS1. In summary, the results of this study suggested that HNF1α-AS1 is involved in the HNF1α-mediated regulation of P450s in the liver at both basal and drug-induced levels.
Collapse
Affiliation(s)
- Yiting Wang
- Department of Pharmacology (Y.W., L.Y., J.L., S.C., G.L., Y.N., P.W., S.H., L.Z.) and Forensic Medicine (W.Y.), School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (L.Y.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut (L.C., X.Z.)
| | - Liang Yan
- Department of Pharmacology (Y.W., L.Y., J.L., S.C., G.L., Y.N., P.W., S.H., L.Z.) and Forensic Medicine (W.Y.), School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (L.Y.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut (L.C., X.Z.)
| | - Jingyang Liu
- Department of Pharmacology (Y.W., L.Y., J.L., S.C., G.L., Y.N., P.W., S.H., L.Z.) and Forensic Medicine (W.Y.), School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (L.Y.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut (L.C., X.Z.)
| | - Shitong Chen
- Department of Pharmacology (Y.W., L.Y., J.L., S.C., G.L., Y.N., P.W., S.H., L.Z.) and Forensic Medicine (W.Y.), School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (L.Y.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut (L.C., X.Z.)
| | - Guangming Liu
- Department of Pharmacology (Y.W., L.Y., J.L., S.C., G.L., Y.N., P.W., S.H., L.Z.) and Forensic Medicine (W.Y.), School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (L.Y.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut (L.C., X.Z.)
| | - Yali Nie
- Department of Pharmacology (Y.W., L.Y., J.L., S.C., G.L., Y.N., P.W., S.H., L.Z.) and Forensic Medicine (W.Y.), School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (L.Y.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut (L.C., X.Z.)
| | - Pei Wang
- Department of Pharmacology (Y.W., L.Y., J.L., S.C., G.L., Y.N., P.W., S.H., L.Z.) and Forensic Medicine (W.Y.), School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (L.Y.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut (L.C., X.Z.)
| | - Weihong Yang
- Department of Pharmacology (Y.W., L.Y., J.L., S.C., G.L., Y.N., P.W., S.H., L.Z.) and Forensic Medicine (W.Y.), School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (L.Y.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut (L.C., X.Z.)
| | - Liming Chen
- Department of Pharmacology (Y.W., L.Y., J.L., S.C., G.L., Y.N., P.W., S.H., L.Z.) and Forensic Medicine (W.Y.), School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (L.Y.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut (L.C., X.Z.)
| | - Xiaobo Zhong
- Department of Pharmacology (Y.W., L.Y., J.L., S.C., G.L., Y.N., P.W., S.H., L.Z.) and Forensic Medicine (W.Y.), School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (L.Y.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut (L.C., X.Z.)
| | - Shengna Han
- Department of Pharmacology (Y.W., L.Y., J.L., S.C., G.L., Y.N., P.W., S.H., L.Z.) and Forensic Medicine (W.Y.), School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (L.Y.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut (L.C., X.Z.)
| | - Lirong Zhang
- Department of Pharmacology (Y.W., L.Y., J.L., S.C., G.L., Y.N., P.W., S.H., L.Z.) and Forensic Medicine (W.Y.), School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (L.Y.); and Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut (L.C., X.Z.)
| |
Collapse
|
59
|
Rowland A, van Dyk M, Warncken D, Mangoni AA, Sorich MJ, Rowland A. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Br J Clin Pharmacol 2018; 84:501-509. [PMID: 29178272 DOI: 10.1111/bcp.13478] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Revised: 10/19/2017] [Accepted: 11/13/2017] [Indexed: 01/01/2023] Open
Abstract
AIM To evaluate the capacity for modafinil to be a perpetrator of metabolic drug-drug interactions by altering cytochrome P450 activity following a single dose and dosing to steady state. METHODS A single centre, open label, single sequence cocktail drug interaction trial. On days 0, 2 and 8 participants were administered an oral drug cocktail comprising 100 mg caffeine, 30 mg dextromethorphan, 25 mg losartan, 1 mg midazolam and 20 mg enteric-coated omeprazole. Timed blood samples were collected prior to and for up to 6 h post cocktail dosing. Between days 2 and 8 participants orally self-administered 200 mg modafinil each morning. RESULTS Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively. Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively. CONCLUSIONS These data support consideration of the risk of clinically relevant metabolic drug-drug interactions perpetrated by modafinil when this drug is co-administered with drugs that are primarily cleared by CYP2C19 (single modafinil dose or steady state modafinil dosing) or CYP3A4 (steady state modafinil dosing only) catalysed metabolic pathways.
Collapse
Affiliation(s)
- Angela Rowland
- Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Madelé van Dyk
- Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - David Warncken
- Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Arduino A Mangoni
- Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Michael J Sorich
- Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Andrew Rowland
- Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, Australia
| |
Collapse
|